Skip to content

High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase

High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Periacetabular (GANZ) Osteotomy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03161938
Acronym
DEX-GANZ
Enrollment
64
Registered
2017-05-22
Start date
2017-04-24
Completion date
2019-08-20
Last updated
2020-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Dysplasia, Postoperative Complications

Brief summary

The aim of this study is to investigate the effect of a single preoperative high-dose steroid injection on complications in the immediate postoperative phase after periacetabular osteotomy. Primary outcome is the proportion of patients who have moderate to severe postoperative pain in the post anaesthesia care unit. Secondary outcomes are organspecific complications in the post anaesthesia phase, pain and nausea the first 5 days, wound infection and readmissions the first 30 days after surgery. The investigators hypothesize that the frequency of moderate to severe pain and organspecific complications in the post anaesthesia care unit will be lower among patients receiving high dose dexamethasone. The investigators hypothesize, that there will be no difference in wound infections or readmissions.

Detailed description

Post-surgery, patients are traditionally observed and treated in post-anesthesia care units (PACU) until they are discharged to the ward (or directly home) assessed by standardized international discharge criteria. The research project Why in PACU? (Rigshospitalet, Denmark), has since the beginning of 2016 systematically collected and analyzed procedure-related complications in the recovery phase. The complications include pain, nausea/vomiting, circulatory and respiratory problems, orthostatic intolerance and cognitive disorders. Common to all the above-mentioned post-operative problems are the possible links to the inflammatory response caused by the surgical trauma. Glucocorticoids can in this context be central for the reduction of acute postoperative organ dysfunctions, caused by the anti-inflammatory effect. In a number of different surgical procedures, single dose, pre-operative glucocorticoids have been shown to reduce post-operative nausea and vomiting (PONV), acute pain and need of opioids as well as accelerate the convalescence. Meta-analyses also showed that single-dose administration of glucocorticoids (methylprednisolone and dexamethasone) for surgical patients is safe as opposed to long-term treatment. The Why in PACU? database shows that 70 % of patients experience moderate to severe pain in the immediate postoperative phase. This is despite a multimodal analgesic regime with preoperative analgesics and local analgesic catheter in the surgical site. Opioids are frequently administered to relieve pain, resulting in sedation, risk of hypoxia and delaying mobilization. Patients having Ganz osteotomy are primarily young women with hipdysplasia, that are otherwise healthy. Lenght of stay is typically 5 days, due to pain and lack of mobilisation. In this study patients are randomized to either high dose (48 mg) or standard/low dose (8 mg) dexamethasone, administered preoperatively. The hypothese is that patients receiving high dose dexamethasone will experience less pain in the immediate postoperative course and receive less opioids. The study is not placebo-controlled since the positive effects of dexamethasone 8 mg on PONV have been shown in numerous trials, and is already being administered to all patients at the clinic. It would therefore not be ethically correct to withdraw from this practise.

Interventions

DRUGDexamethasone

intravenous

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* planned unilateral periacetabular osteotomy * informed signed consent

Exclusion criteria

* Chronic/ongoing (\<30 days) use of glucocorticoids (except inhalation therapy) * ongoing (\<30 days) use of immunosuppressive therapy * insulin dependent diabetes * pregnancy/breastfeeding * allergies toward study medication, or medication in the standard treatment * surgery cannot be performed

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Moderate to Severe Postoperative Pain12 hoursModerate to severe pain (NRS \> 3) in the post-anesthesia care unit (PACU)

Secondary

MeasureTime frameDescription
Lenght of Stay, Hospital1 weekTotal lenght of stay, Hospital
Pain Scores, PACU12 hoursDifferences between groups in maximal and average pain score during PACU stay. Pain scores are measured on a numeric rating scale (NRS), 0-10. 0 is no pain, 10 is worst pain imaginable.
Complications24 hoursPatients with complications requiring treatment the first 24 hours (PACU and ward)
Self Reported Postoperative Painpostoperative day 0 to 4, once a daySelf-reported pain on a Numeric rating scale (NRS), NRS 0-10, 0 = no pain, 10= worst pain imaginable. Reported once daily, postoperative days 0 to 4
Lenght of Stay, PACU24 hoursTotal lenght of stay in PACU
Number of Patients With Sleep Problems4 daysSelf-reported quality of sleep (days 0-4). Questionnaire. Results dichotomized to sleep problems (trouble falling asleep, frequent awakenings, no sleep) or no sleep problems.
Number of Patients With Feelings of Anxiety, Unrest and/or Sadnesspostoperative day 0 to 4, once a daySelf-reported feelings of anxiety, unrest, sadness (days 0-4). Questionnaire
Number of Patients Readmitted to Hospital Within 30 Days30 daysAny readmission within 30 days
Number of Patients With Wound Infections Within 30 Days30 daysAny wound infections/complications
Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4postoperative day 0 to 4, once a dayPatients reporting PONV and/or receiving antiemetic medication on postoperative days 0 to 4

Countries

Denmark

Participant flow

Participants by arm

ArmCount
Dexamethasone 48 mg
Dexamethasone 48 mg pre-operative, single shot injection Dexamethasone: intravenous
32
Dexamethasone 8 mg
Dexamethasone 8 mg pre-operative, single shot injection Dexamethasone: intravenous
32
Total64

Baseline characteristics

CharacteristicDexamethasone 48 mgDexamethasone 8 mgTotal
Age, Continuous28 years
STANDARD_DEVIATION 8
29 years
STANDARD_DEVIATION 7
29 years
STANDARD_DEVIATION 8
Bleeding467 ml
STANDARD_DEVIATION 301
510 ml
STANDARD_DEVIATION 295
500 ml
STANDARD_DEVIATION 296
Body Mass Index (BMI)23 kg/m^2
STANDARD_DEVIATION 3
23 kg/m^2
STANDARD_DEVIATION 3
23 kg/m^2
STANDARD_DEVIATION 3
Comorbidities, none30 Participants27 Participants57 Participants
Daily intake of analgesics, preoperative4 Participants6 Participants10 Participants
Daily intake of opioids, preoperative2 Participants2 Participants4 Participants
Operating time71 minutes
STANDARD_DEVIATION 20
69 minutes
STANDARD_DEVIATION 13
70 minutes
STANDARD_DEVIATION 17
Previous operation (contralateral periacetabular osteotomy)3 Participants9 Participants12 Participants
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
27 Participants24 Participants51 Participants
Sex: Female, Male
Male
5 Participants8 Participants13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 320 / 32
other
Total, other adverse events
0 / 320 / 32
serious
Total, serious adverse events
1 / 320 / 32

Outcome results

Primary

Number of Participants With Moderate to Severe Postoperative Pain

Moderate to severe pain (NRS \> 3) in the post-anesthesia care unit (PACU)

Time frame: 12 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Dexamethasone 48 mgNumber of Participants With Moderate to Severe Postoperative Pain26 Participants
Dexamethasone 8 mgNumber of Participants With Moderate to Severe Postoperative Pain22 Participants
Comparison: Null hypothesis: Patients receiving 48 mg of preoperative dexamethasone have less postoperative pain. Power calculation: Acute pain is reduced from 70% to 35% for patients receiving 48 mg of dexamathesone, 80% power, 0.05 statistical significance level.p-value: 0.24895% CI: [0.159, 1.62]Chi-squared, Corrected
Secondary

Complications

Patients with complications requiring treatment the first 24 hours (PACU and ward)

Time frame: 24 hours

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Dexamethasone 48 mgComplications24 Participants
Dexamethasone 8 mgComplications25 Participants
p-value: 0.76895% CI: [0.374, 3.793]Chi-squared, Corrected
Secondary

Lenght of Stay, Hospital

Total lenght of stay, Hospital

Time frame: 1 week

ArmMeasureValue (MEDIAN)
Dexamethasone 48 mgLenght of Stay, Hospital78 hours
Dexamethasone 8 mgLenght of Stay, Hospital77 hours
p-value: 0.468Wilcoxon (Mann-Whitney)
Secondary

Lenght of Stay, PACU

Total lenght of stay in PACU

Time frame: 24 hours

ArmMeasureValue (MEDIAN)
Dexamethasone 48 mgLenght of Stay, PACU2 hours
Dexamethasone 8 mgLenght of Stay, PACU3 hours
p-value: 0.519Wilcoxon (Mann-Whitney)
Secondary

Number of Patients Readmitted to Hospital Within 30 Days

Any readmission within 30 days

Time frame: 30 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Dexamethasone 48 mgNumber of Patients Readmitted to Hospital Within 30 Days1 Participants
Dexamethasone 8 mgNumber of Patients Readmitted to Hospital Within 30 Days3 Participants
p-value: 0.613Chi-squared, Corrected
Secondary

Number of Patients With Feelings of Anxiety, Unrest and/or Sadness

Self-reported feelings of anxiety, unrest, sadness (days 0-4). Questionnaire

Time frame: postoperative day 0 to 4, once a day

Population: Missing data from questionnaires, missing at random

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 1 : restlessness3 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 2 : fatigue21 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 0 : restlessness11 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 3 : sadness9 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 1 : fatigue20 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 3 : restlessness9 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 1 : sadness6 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 3 : fatigue17 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 2 : sadness8 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 4 : sadness8 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 0 : fatigue23 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 4 : restlessness10 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 2 : restlessness6 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 4 : fatigue17 Participants
Dexamethasone 48 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 0 : sadness8 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 4 : fatigue10 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 0 : sadness2 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 0 : restlessness8 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 0 : fatigue21 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 1 : sadness4 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 1 : restlessness8 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 1 : fatigue17 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 2 : sadness8 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 2 : restlessness11 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 2 : fatigue14 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 3 : sadness6 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 3 : restlessness8 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 3 : fatigue13 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 4 : sadness5 Participants
Dexamethasone 8 mgNumber of Patients With Feelings of Anxiety, Unrest and/or SadnessDay 4 : restlessness3 Participants
Comparison: day 0, sadnessp-value: 0.075Chi-squared, Corrected
Comparison: day 0, restlessnessp-value: 0.447Chi-squared, Corrected
Comparison: Day 0, fatiguep-value: 0.703Chi-squared, Corrected
Comparison: Day 1, sadnessp-value: 0.731Chi-squared, Corrected
Comparison: Day 1, restlessnessp-value: 0.052Chi-squared, Corrected
Comparison: Day 1, fatiguep-value: 0.807Chi-squared, Corrected
Comparison: Day 2, sadnessp-value: 0.371Chi-squared, Corrected
Comparison: Day 2, restlessnessp-value: 0.064Chi-squared, Corrected
Comparison: day 2, fatiguep-value: 0.11Chi-squared, Corrected
Comparison: Day 3, sadnessp-value: 0.531Chi-squared, Corrected
Comparison: Day 3, restlessnessp-value: 0.954Chi-squared, Corrected
Comparison: Day 3, fatiguep-value: 0.526Chi-squared, Corrected
Comparison: Day 4, sadnessp-value: 0.491Chi-squared, Corrected
Comparison: Day 4, restlessnessp-value: 0.042Chi-squared, Corrected
Comparison: Day 4, fatiguep-value: 0.097Chi-squared, Corrected
Secondary

Number of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4

Patients reporting PONV and/or receiving antiemetic medication on postoperative days 0 to 4

Time frame: postoperative day 0 to 4, once a day

Population: Missing data day 4 due to discharge from hospital

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Dexamethasone 48 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 16 Participants
Dexamethasone 48 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 37 Participants
Dexamethasone 48 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 29 Participants
Dexamethasone 48 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 43 Participants
Dexamethasone 48 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 07 Participants
Dexamethasone 8 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 42 Participants
Dexamethasone 8 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 08 Participants
Dexamethasone 8 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 19 Participants
Dexamethasone 8 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 211 Participants
Dexamethasone 8 mgNumber of Patients With Post Operative Nausea and Vomiting (PONV) Postoperative Days 0 to 4Day 34 Participants
Comparison: Day 0p-value: 0.768Chi-squared, Corrected
Comparison: Day 1p-value: 0.376Chi-squared, Corrected
Comparison: Day 2p-value: 0.59Chi-squared, Corrected
Comparison: Day 3p-value: 0.32Chi-squared, Corrected
Comparison: day 4p-value: 0.666Chi-squared, Corrected
Secondary

Number of Patients With Sleep Problems

Self-reported quality of sleep (days 0-4). Questionnaire. Results dichotomized to sleep problems (trouble falling asleep, frequent awakenings, no sleep) or no sleep problems.

Time frame: 4 days

Population: Missing data from questionnaires, missing at random, not filled out or not sent back

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Dexamethasone 48 mgNumber of Patients With Sleep ProblemsDay 19 Participants
Dexamethasone 48 mgNumber of Patients With Sleep ProblemsDay 39 Participants
Dexamethasone 48 mgNumber of Patients With Sleep ProblemsDay 28 Participants
Dexamethasone 48 mgNumber of Patients With Sleep ProblemsDay 48 Participants
Dexamethasone 48 mgNumber of Patients With Sleep ProblemsDay 013 Participants
Dexamethasone 8 mgNumber of Patients With Sleep ProblemsDay 48 Participants
Dexamethasone 8 mgNumber of Patients With Sleep ProblemsDay 012 Participants
Dexamethasone 8 mgNumber of Patients With Sleep ProblemsDay 113 Participants
Dexamethasone 8 mgNumber of Patients With Sleep ProblemsDay 29 Participants
Dexamethasone 8 mgNumber of Patients With Sleep ProblemsDay 39 Participants
Comparison: day 0p-value: >0.999Chi-squared, Corrected
Comparison: day 1p-value: 0.154Chi-squared, Corrected
Comparison: day 2p-value: 0.447Chi-squared, Corrected
Comparison: day 3p-value: 0.678Chi-squared, Corrected
Comparison: day 4p-value: 0.604Chi-squared, Corrected
Secondary

Number of Patients With Wound Infections Within 30 Days

Any wound infections/complications

Time frame: 30 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Dexamethasone 48 mgNumber of Patients With Wound Infections Within 30 Days0 Participants
Dexamethasone 8 mgNumber of Patients With Wound Infections Within 30 Days0 Participants
Secondary

Pain Scores, PACU

Differences between groups in maximal and average pain score during PACU stay. Pain scores are measured on a numeric rating scale (NRS), 0-10. 0 is no pain, 10 is worst pain imaginable.

Time frame: 12 hours

ArmMeasureGroupValue (MEDIAN)
Dexamethasone 48 mgPain Scores, PACUAverage pain2 score on a scale (numeric rating scale)
Dexamethasone 48 mgPain Scores, PACUMaximal pain5 score on a scale (numeric rating scale)
Dexamethasone 8 mgPain Scores, PACUAverage pain2 score on a scale (numeric rating scale)
Dexamethasone 8 mgPain Scores, PACUMaximal pain5 score on a scale (numeric rating scale)
Comparison: Maximal painp-value: 0.913Wilcoxon (Mann-Whitney)
Comparison: Average painp-value: 0.722Wilcoxon (Mann-Whitney)
Secondary

Self Reported Postoperative Pain

Self-reported pain on a Numeric rating scale (NRS), NRS 0-10, 0 = no pain, 10= worst pain imaginable. Reported once daily, postoperative days 0 to 4

Time frame: postoperative day 0 to 4, once a day

Population: Missing data, missing at random

ArmMeasureGroupValue (MEAN)Dispersion
Dexamethasone 48 mgSelf Reported Postoperative PainDay 23 score on a scaleStandard Deviation 2
Dexamethasone 48 mgSelf Reported Postoperative PainDay 14 score on a scaleStandard Deviation 2
Dexamethasone 48 mgSelf Reported Postoperative PainDay 33 score on a scaleStandard Deviation 2
Dexamethasone 48 mgSelf Reported Postoperative PainDay 43 score on a scaleStandard Deviation 2
Dexamethasone 48 mgSelf Reported Postoperative PainDay 03 score on a scaleStandard Deviation 2
Dexamethasone 8 mgSelf Reported Postoperative PainDay 43 score on a scaleStandard Deviation 2
Dexamethasone 8 mgSelf Reported Postoperative PainDay 04 score on a scaleStandard Deviation 2
Dexamethasone 8 mgSelf Reported Postoperative PainDay 14 score on a scaleStandard Deviation 2
Dexamethasone 8 mgSelf Reported Postoperative PainDay 24 score on a scaleStandard Deviation 2
Dexamethasone 8 mgSelf Reported Postoperative PainDay 33 score on a scaleStandard Deviation 2
p-value: 0.133Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026